Oxurion (TBGNF) Stock Price, News & Analysis

Company Overview

Oxurion NV, formerly known as ThromboGenics, is a Belgian biotechnology company that historically focused on developing treatments for retinal diseases, particularly diabetic eye conditions. The company’s research programs were designed to address vision loss associated with diabetic macular edema and other disorders affecting the retina.

Oxurion’s principal investigational programs included THR-149, a plasma kallikrein inhibitor intended for the treatment of diabetic macular edema, and THR-687, an integrin antagonist developed for retinal vascular diseases. Both programs were administered by intravitreal injection and were evaluated in clinical studies. The company also developed ocriplasmin, marketed as Jetrea, for symptomatic vitreomacular adhesion before shifting its focus toward diabetic eye disease.

Founded as ThromboGenics, Oxurion was headquartered in Leuven, Belgium, and conducted development activities through clinical and commercial partnerships in international markets. The company later encountered financial and operational difficulties and pursued measures to restructure its business. Information about its current operating activities and leadership is limited, and its historical pipeline should not be interpreted as evidence of currently available products or active clinical programs.

Key Stats

• Today's Range: $0.17 to $0.17
• 50-Day Range: $0.17 to $0.17
• 52-Week Range: $0.17 to $0.29
• Volume: N/A
• Average Volume: 440 shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: OTCMKTS:TBGNF
• CIK: N/A
• Web: www.oxurion.com
• Phone: (321) 675-1317
• Fax: N/A
• Employees: 27
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A